|1.||Franke, R P: 1 article (01/2013)|
|2.||Jung, F: 1 article (01/2013)|
|3.||Mrowietz, C: 1 article (01/2013)|
|4.||Gerk, U: 1 article (01/2013)|
|5.||Schmidt, Claudia: 1 article (03/2008)|
|6.||Trautmann, Axel: 1 article (03/2008)|
|7.||Seitz, Cornelia S: 1 article (03/2008)|
|8.||Trcka, Jiri: 1 article (03/2008)|
|9.||Bröcker, Eva-B: 1 article (03/2008)|
|10.||Gross, Gerd E: 1 article (03/2008)|
01/01/1997 - "Significantly more patients in the ioxaglate group (50%) than in the iopentol group (30%) reported increased knee pain during the 4 days following the examination (p < 0.05). "
02/01/1996 - "The comparison of heat and pain sensations after the second injection showed a less distinct difference with a scale rating of 60 for iomeprol and of 65 for iopentol. "
07/01/1992 - "Delayed arm pain was probably due to contrast medium induced thrombosis in 1% following iopentol and in 8% following metrizoate. "
01/01/1997 - "Both iopentol and ioxaglate are effective and safe contrast media for use in knee arthrography, but iopentol induces less postprocedural pain."
02/01/2001 - "Iomeprol caused significantly less heat/pain than iopentol in one study; it showed similar safety and tolerability to the nonionic dimer iodixanol, the two agents causing no or modest, superimposable pain and heat sensation at injection and showing similar renal tolerability after intra-arterial injection. "
|2.||Body Weight (Weight, Body)
01/01/1987 - "In order to study the pharmacokinetic properties, iopentol 350 mg I/ml was administered intravenously to healthy male volunteers at 3 dose levels (0.3, 0.6 and 1.2 g I/kg body weight). "
01/01/1990 - "Twenty-four healthy male volunteers, allocated to three dose groups, were given iopentol intravenously in doses of 0.3, 0.6, and 1.2 g I/kg body weight, respectively. "
01/01/1987 - "Iopentol was well tolerated when injected intravenously into 24 healthy male volunteers in doses of 300 to 1,200 mg I/kg body weight and was excreted almost entirely in the urine in unchanged form. "
02/01/1992 - "A new nonionic dimeric contrast medium (CM), iodixanol, was intravenously administered to 40 healthy male volunteers in doses of 0.3-1.2 g of iodine per kilogram of body weight, nonionic monomeric iopamidol and iopentol were administered to 20 others, and the renal effects were studied up to 120 hours after administration. "
|3.||Renal Insufficiency (Renal Failure)
09/01/1992 - "In conclusion, this study shows an extrarenal elimination of iopentol and demonstrates a substantial increase in the fecal elimination in patients with severe renal failure."
02/01/1992 - "We conclude that abdominal aortography with iopentol can be performed without effects on renal glomerular or tubular function parameters in patients with advanced renal failure. "
03/01/1989 - "The addition of 77 or 154 mmol Na+/l significantly decreased the frequency of ventricular fibrillation of both meglumine diatrizoate (3% and 6%) and iopentol (0%). "
03/01/1989 - "Iopentol without sodium caused a significantly lower frequency of ventricular fibrillation (17%). "
05/01/1989 - "Perfusion of the isolated rabbit heart with solutions (350 mg I/ml) of the non-ionic contrast media iohexol and iopentol, both containing NaCl (20 mmol/l), caused a significantly lower frequency of ventricular fibrillation (VF) than solutions without NaCl. "
03/01/1989 - "Meglumine diatrizoate with sodium added caused a lower frequency of ventricular fibrillation than iopentol without sodium. "
01/01/1987 - "Frequencies of ventricular fibrillation were significantly lower (p less than 0.05) after iopentol (0%) and iohexol (3%) than after metrizoate (22%). "
|5.||Chronic Kidney Failure (Chronic Renal Failure)
09/01/1992 - "Pharmacokinetics of iopentol in patients with chronic renal failure."
02/01/1992 - "Iopentol in patients with chronic renal failure: its effects on renal function and its use as glomerular filtration rate parameter."
02/01/1992 - "Iopentol (mean dose 0.42 g I kg-1) was administered for abdominal aortography and pelvic angiography in 10 patients with advanced non-diabetic chronic renal failure (S-creatinine 672 +/- 259 mumol l-1, mean +/- SD). "
|1.||Ioxaglic Acid (Ioxaglate Meglumine)